Quanterix Corp (QTRX) Expected to Post Earnings of -$0.39 Per Share

Brokerages expect Quanterix Corp (NASDAQ:QTRX) to announce earnings per share (EPS) of ($0.39) for the current fiscal quarter, according to Zacks Investment Research. Three analysts have provided estimates for Quanterix’s earnings. The lowest EPS estimate is ($0.44) and the highest is ($0.34). Quanterix posted earnings per share of ($0.33) in the same quarter last year, which would suggest a negative year-over-year growth rate of 18.2%. The company is scheduled to announce its next quarterly earnings report on Tuesday, May 21st.

According to Zacks, analysts expect that Quanterix will report full-year earnings of ($1.44) per share for the current financial year, with EPS estimates ranging from ($1.54) to ($1.33). For the next year, analysts forecast that the firm will post earnings of ($0.69) per share, with EPS estimates ranging from ($0.80) to ($0.57). Zacks’ earnings per share averages are an average based on a survey of research analysts that follow Quanterix.

Quanterix (NASDAQ:QTRX) last issued its quarterly earnings data on Monday, March 18th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.17). Quanterix had a negative return on equity of 62.68% and a negative net margin of 83.80%. The company had revenue of $10.88 million for the quarter, compared to analyst estimates of $9.69 million.

Several brokerages have issued reports on QTRX. Canaccord Genuity reiterated a “buy” rating and issued a $29.00 price target on shares of Quanterix in a research note on Friday, March 8th. ValuEngine upgraded shares of Quanterix from a “hold” rating to a “buy” rating in a research note on Thursday, January 31st. Finally, Zacks Investment Research lowered shares of Quanterix from a “hold” rating to a “sell” rating in a research note on Friday, January 25th.

In other Quanterix news, Chairman E Kevin Hrusovsky sold 1,903 shares of Quanterix stock in a transaction on Friday, March 1st. The shares were sold at an average price of $25.00, for a total value of $47,575.00. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 11,709 shares of company stock worth $277,050 over the last quarter. Company insiders own 31.60% of the company’s stock.

A number of hedge funds have recently modified their holdings of QTRX. Bank of Montreal Can raised its holdings in Quanterix by 3,159.2% during the first quarter. Bank of Montreal Can now owns 3,911 shares of the company’s stock worth $101,000 after buying an additional 3,791 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in Quanterix by 5,803.2% during the first quarter. BNP Paribas Arbitrage SA now owns 1,830 shares of the company’s stock worth $47,000 after buying an additional 1,799 shares during the last quarter. Boston Financial Mangement LLC acquired a new position in Quanterix during the first quarter worth $282,000. Geode Capital Management LLC raised its holdings in Quanterix by 23.6% during the fourth quarter. Geode Capital Management LLC now owns 91,590 shares of the company’s stock worth $1,677,000 after buying an additional 17,516 shares during the last quarter. Finally, Macquarie Group Ltd. acquired a new position in Quanterix during the fourth quarter worth $100,000. Hedge funds and other institutional investors own 51.69% of the company’s stock.

QTRX stock traded down $0.35 during midday trading on Wednesday, hitting $22.40. The company’s stock had a trading volume of 300 shares, compared to its average volume of 80,990. The company has a current ratio of 3.28, a quick ratio of 2.95 and a debt-to-equity ratio of 0.19. Quanterix has a twelve month low of $13.00 and a twelve month high of $26.48. The firm has a market capitalization of $510.99 million, a P/E ratio of -15.66 and a beta of 1.49.

About Quanterix

Quanterix Corporation, a life sciences company, develops and markets ultra-sensitive digital immunoassay platform that advances precision health for life sciences research and diagnostics in North America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Simoa HD-1 instrument, a sensitive automated multiplex protein detection platform; and SR-X instrument that enables researchers to apply Simoa detection technology in various applications, including direct detection of nucleic acids.

Recommended Story: What are different types of coverage ratios?

Get a free copy of the Zacks research report on Quanterix (QTRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Quanterix (NASDAQ:QTRX)

Receive News & Ratings for Quanterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quanterix and related companies with MarketBeat.com's FREE daily email newsletter.